Diaminopyrazoles

A compound which is selected from the group consisting of:

• 4-{[5-(2,2-dimethyl-propylamino)-1,3-dimethyl-1H-pyrazol-4-ylamino]-methyl}-benzonitrile or a pharmaceutically acceptable salt thereof;
• N(3)-(2,2-dimethyl-propyl)-N(4)-(4-fluoro-benzyl)-2,5-dimethyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• N(4)-(2,4-dichloro-benzyl)-N(3)-(2,2-dimethyl-propyl)-2,5-dimethyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• 4-{[5-(2,2-dimethyl-butylamino)-1,3-dimethyl-1H-pyrazol-4-ylamino]-methyl}-benzonitrile or a pharmaceutically acceptable salt thereof;
• N(4)-(2,4-difluoro-benzyl)-N(3)-(2,2-dimethyl-propyl)-2,5-dimethyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• N(3)-(2,2-dimethyl-propyl)-2,5-dimethyl-N(4)-(2,4,6-trimethyl-benzyl)-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• N(4)-benzyl-N(3)-(2,2-dimethyl-butyl)-2,5-dimethyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• N(3)-(2,2-dimethyl-propyl)-2,5-dimethyl-N(4)-phenyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• N(4)-(4-chloro-2-methyl-phenyl)-N(3)-(2,2-dimethyl-propyl)-2,5-dimethyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof;
• 4-[5-(2,2-dimethyl-propylamino)-1,3-dimethyl-1H-pyrazol-4-ylamino]-benzonitrile or a pharmaceutically acceptable salt thereof;
• and
• N(4)-(4-chloro-phenyl)-N(3)-(2,2-dimethyl-propyl)-2,5-dimethyl-2H-pyrazole-3,4-diamine or a pharmaceutically acceptable salt thereof.

A method of treating disorders associated with spastic or excessive smooth muscle contraction of the urinary tract in a mammal having such disorder which comprises administering to said mammal of a therapeutically effective amount of a compound according to the formula

• wherein:
• R1 and R2 are independently straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbons atoms, or cycloalkyl of 3 to 6 carbons atoms where R1 and R2 may be optionally substituted by F, Cl, Br, I, OH, NH2, cyano, C1-C6 alkoxy, C1-C6 alkylthio, COOH or COOC1-C6 alkyl;
• R3 is an aryl optionally substituted with 1 to 4 groups selected independently from straight chain C1-C6 alkyl, branched alkyl of 3 to 6 carbons, or a cycloalkyl of 3 to 10 carbons;
• C1-C6 alkoxy, cyano, F, Cl, Br, C1-C6 alkylthio, CO2R1, CONH2, OH, NH2, and NO2;
• wherein aryl is phenyl, naphthalene, anthracene or phenanthrene;
• R4 is a straight chain alkyl group of 1 to 10 carbons atoms, a branched alkyl of 3 to 10 carbons, a cycloalkyl of 3 to 10 carbons, all of which may be optionally substituted by one or more F or Cl atoms;
• n is0 or 1;
• all crystalline forms;
• an enantiomer or diastereomer,
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to the formula

• wherein:
• R1 and R2 are independently straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbons atoms, or cycloalkyl of 3 to 6 carbons atoms where R1 and R2 may be optionally substituted by F, Cl, Br, I, OH, NH2, cyano, C1-C6 alkoxy, C1-C6 alkylthio, COOH or COOC1-C6 alkyl;
• R3 is an aryl optionally substituted with 1 to 4 groups selected independently from straight chain C1-C6 alkyl, branched alkyl of 3 to 6 carbons, or a cycloalkyl of 3 to 10 carbons;
• C1-C6 alkoxy, cyano, F, Cl, Br, C1-C6 alkylthio, CO2R1, CONH2, OH, NH2, and NO2;
• wherein aryl is phenyl, naphthalene, anthracene or phenanthrene;
• R4 is a straight chain alkyl group of 1 to 10 carbons atoms, a branched alkyl of 3 to 10 carbons, a cycloalkyl of 3 to 10 carbons, all of which may be optionally substituted by one or more F or Cl atoms;
• n is 0 or 1;
• all crystalline forms;
• an enantiomer or diastereomer,
• or a pharmaceutically acceptable salt thereof.